Findings from a retrospective study including 1,200 women provide reassurance to breast cancer survivors who are contemplating pregnancy. In the study, women who became pregnant after an early breast cancer diagnosis, including those with estrogen receptor (ER)-positive tumors, did not have a higher chance of cancer recurrence and death than those who did not become pregnant.
Breast cancer is the most common cancer in women of reproductive age. Taking into account current trends toward delaying childbearing, breast cancer in young women may occur before the completion of reproductive plans. Although half of young women with newly diagnosed breast cancer report interest in having children, less than 10% becomes pregnant after treatment. In fact, of all cancer survivors, breast cancer survivors are the least likely to have a baby after diagnosis. Doctors and patients have long been concerned that pregnancy could increase the chance of breast cancer recurrence, particularly in women with ER-positive disease. Because ER-positive breast cancer is fueled by estrogen, the fear is that hormone levels during pregnancy could coax any occult cancer cells to grow. Another concern regarding pregnancy in women with ER-positive cancer consists of the need to interrupt adjuvant hormone therapy before trying to achieve a pregnancy.
With 1,207 patients, this is the largest study to investigate the safety of pregnancy after breast cancer and the only one to address this question specifically in women with ER-positive breast cancer, the most common type of breast cancer. This study included women who were diagnosed with non-metastatic breast cancer before 2008, under the age of 50. The majority (57%) had ER-positive cancer, and more than 40% of patients had poor prognostic factors, such as large tumor size and cancer spread to the axillary lymph nodes. Among the 1,207 patients included in the study, 333 became pregnant, and 874 did not. As per the case-control study design, researchers matched each patient who became pregnant with three patients who had similar cancer characteristics but did not become pregnant. The median time from diagnosis to conception was 2.4 years. Women with ER-positive breast cancer tended to achieve pregnancy later than those with ER-negative disease. In fact, 23% of patients with ER-positive disease had a pregnancy beyond 5 years from diagnosis as compared to 7% in those with ER-negative tumors.
After a median follow-up of about 10 years from cancer diagnosis, there was no difference in disease-free survival between women who became pregnant and those who did not (HR[95%CI]: 0.85[0.68-1.06]; p= 0.15), irrespective of ER status (ER-positive: HR[95%CI]: 0.94[0.70-1.26]; p= 0.68), ER-negative: HR[95%CI]: 0.75[0.53-1.06]; p=0.10). Secondary analyses showed that there was no difference in disease-free survival compared to women who did not become pregnant, irrespective of whether women completed the pregnancy or had an abortion, became pregnant less than two years or more than two years from breast cancer diagnosis, and whether patients had breastfed. Among survivors of ER-positive cancer, there was also no difference in overall survival between women who became pregnant and those who did not (HR[95%CI]: 0.84[0.60-1.18]; p= 0.32). Interestingly, survivors of ER-negative breast cancer who became pregnant had a 42% lower chance of dying than those who did not become pregnant. In this respect, the authors stated that it is possible that pregnancy could be a protective factor for patients with ER-negative breast cancer, through either immune system mechanisms or hormonal mechanisms. However, more research is needed to further elucidate this. There were limited data on breastfeeding in this study (64 patients, with 25 women who reported having breastfed their newborn), but the results suggest that breastfeeding is feasible, even after breast surgery.
These findings confirm that pregnancy after breast cancer should not be discouraged, even for women with ER-positive cancer. The study has also some limitations. Although large, this study had limited information on the use of assisted reproductive technologies (such as in vitro fertilization) in breast cancer survivors, and the HER2 status was unknown for about 80% of the women. Further research is also needed to study the effect of pregnancy on health outcomes of women with BRCA mutations, a group that generally develops breast cancer at a younger age. A large clinical trial (the POSITIVE study) is currently underway looking into the impact of interrupting adjuvant hormone therapy to allow for pregnancy in women with ER-positive breast cancer. This study will also provide further insight on the impact of reproductive technologies and breastfeeding.
Lambertini M, N. Kroman N, Ameye L, et al. Safety of pregnancy in patients (pts) with history of estrogen receptor positive (ER+) breast cancer (BC): Long-term follow-up analysis from a multicenter study. Presented at ASCO 2017; Abstract 10066.